Peter Johnston, MD
Interventional Cardiology · Baltimore, MDNPI 1629128830
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,000 of the $4,427 with a category attached, or 90.4%. Astrazeneca UK Limited accounts for 90.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $4,250 and has fallen 97.7% since, to $96 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MD, where the typical reported total is $7,370.
Across 7 payments — averaging $632.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$4K
- Biocardia, Inc.$250
- Boston Scientific$96
- Terumo Medical Corporation$26
- Philips North America LLC$25
- Abiomed$17
- plus $13 from 1 others
What the payments were for
- Consulting fees$4,00090%
- Food & beverage$42710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 1 | $4,000 |
| Biocardia, Inc. | 1 | $250 |
| Boston Scientific | 1 | $96 |
| Terumo Medical Corporation | 1 | $26 |
| Philips North America LLC | 1 | $25 |
| Abiomed | 1 | $17 |
| Medtronic | 1 | $13 |
How this compares
$4,427 in reported general payments places this provider in the 35th percentile of 71 interventional cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 34 | $35,422 |
| JardianceEmpagliflozin | 30 | $26,973 |
| EntrestoSacubitril/Valsartan | 27 | $26,971 |
| XareltoRivaroxaban | 14 | $11,298 |
| Atorvastatin Calcium | 161 | $2,215 |
| Metoprolol Succinate | 120 | $1,822 |
| Ezetimibe | 31 | $893 |
| Rosuvastatin Calcium | 31 | $575 |
| ClopidogrelClopidogrel Bisulfate | 42 | $520 |
| Amlodipine Besylate | 52 | $457 |
| Losartan Potassium | 59 | $337 |
| Lisinopril | 56 | $333 |
| Nitroglycerin | 26 | $315 |
| Carvedilol | 35 | $252 |
| Metoprolol Tartrate | 12 | $218 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Baltimore
- Aloke FinnBaltimore$575K
- John WangBaltimore$138K
- Diljon ChahalBaltimore$78K
- Jon ResarBaltimore$40K
- Faisal RahmanBaltimore$36K
- Matthew VossBaltimore$33K
- Hooman BakhshiBaltimore$32K
- Daniel AmbinderBaltimore$32K
- Rani HasanBaltimore$22K
- Ajar KocharBaltimore$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.